Skip to main content
Canna~Fangled Abstracts

Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies

By October 6, 2021October 7th, 2021No Comments
Review
. 2021 Oct 6.

doi: 10.1007/s00213-021-05960-2.

Online ahead of print.
Dimitri Daldegan-Bueno 1, Lucas O Maia 2, Michelle Glass 3, Didier Jutras-Aswad 4 5, Benedikt Fischer 6 7 8 9
Affiliations 

Abstract

Rationale: The growing prevalence of psychostimulant (including amphetamine) use and associated health harms, with limited treatment options, present a global challenge. There is an increasing availability and medical applications of cannabinoids, and growing interest in their therapeutic potential for addictive disorders.

Objectives: The objective of this study is to review available data regarding cannabis/cannabinoid co-use or exposure on amphetamine-related outcomes.

Methods: Towards the present scoping review, we systematically searched four databases (Medline, Web-of-Science, CINAHL Plus and PsycInfo) using cannabis/cannabinoid and amphetamine text-terms identifying peer-reviewed, English-language studies published in 2000-2020 involving multiple methods approaches among both human and animal study samples, assessing the association of co-use/administration of cannabis/cannabinoids products with non-medical amphetamines on biological, behavioural or health outcomes.

Results: Twenty-five articles were included. Pre-clinical studies (n = 15) found mostly protective effects of single or repeated cannabinoids administration on rodents in amphetamine addiction models, amphetamine-induced models of human mental disorders (e.g. schizophrenia) and amphetamine-induced neurotoxicity. Human studies (n = 10) were more heterogeneously designed (e.g. cross-sectional, case-control, longitudinal) and assessed natural ongoing cannabis and methamphetamine use or dependence, showing mostly enhanced harms in a diversity of outcomes (e.g. mental health, methamphetamine use, cognition).

Conclusions: While human studies suggest cannabis use as an adverse risk factor among non-medical amphetamine users, pre-clinical studies suggest therapeutic potential of cannabinoids, especially cannabidiol, to alleviate amphetamine addiction and harms, including treatment outcomes. Given increasing psychostimulant harms but lack of care options, rigorous, high-quality design studies should aim to translate and investigate pre-clinical study results for potential therapeutic benefits of cannabinoids for amphetamine use/abuse in human subjects.

 

Keywords: Addictive behaviour, Amphetamines, Cannabidiol, Cannabinoids, Cannabis, Co-use, Exposure, Review, Tetrahydrocannabinol, Translational research

References

    1. Abrams DI (2018) The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med 49:7–11. https://doi.org/10.1016/j.ejim.2018.01.003 – DOI – PubMed
    1. Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS, Innis RB (2000) Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 157:1108–1114. https://doi.org/10.1176/appi.ajp.157.7.1108 – DOI – PubMed
    1. Andrade T, Santiago L, Amari E, Fischer B (2011) ‘What a pity!’ – exploring the use of ‘pitilho’ as harm reduction among crack users in Salvador Brazil. Drugs Ed Prev Policy 18:382–386. https://doi.org/10.3109/09687637.2010.506898 – DOI
    1. Anggadiredja K, Nakamichi M, Hiranita T, Tanaka H, Shoyama Y, Watanabe S, Yamamoto T (2004) Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology 29:1470–1478. https://doi.org/10.1038/sj.npp.1300454 – DOI – PubMed
    1. Arksey H, O’Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8:19–32. https://doi.org/10.1080/1364557032000119616 – DOI

Publication types

Leave a Reply